Zimmer Biomet Holdings (STU:ZIM) Total Liabilities : €9,047 Mil (As of Mar. 2025)

View and export this data going back to . Start your Free Trial

What is Zimmer Biomet Holdings Total Liabilities?

Zimmer Biomet Holdings's Total Liabilities for the quarter that ended in Mar. 2025 was €9,047 Mil.

Zimmer Biomet Holdings's quarterly Total Liabilities increased from Sep. 2024 (€8,412.73 Mil) to Dec. 2024 (€8,489.09 Mil) and increased from Dec. 2024 (€8,489.09 Mil) to Mar. 2025 (€9,046.59 Mil).

Zimmer Biomet Holdings's annual Total Liabilities declined from Dec. 2022 (€8,532.82 Mil) to Dec. 2023 (€8,261.07 Mil) but then increased from Dec. 2023 (€8,261.07 Mil) to Dec. 2024 (€8,489.09 Mil).

Zimmer Biomet Holdings Total Liabilities Historical Data

The historical data trend for Zimmer Biomet Holdings's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zimmer Biomet Holdings Total Liabilities Chart

Zimmer Biomet Holdings Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Liabilities

Get a 7-Day Free Trial

10,043.44

9,549.15

8,532.82

8,261.07

8,489.09

Zimmer Biomet Holdings Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Total Liabilities	Get a 7-Day Free Trial															8,138.69	8,147.89	8,412.73	8,489.09	9,046.59

Zimmer Biomet Holdings Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Zimmer Biomet Holdings's Total Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	2340.61	+	(5101.228	+	710.615
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	336.638	+	0	+	0)
	=	8,489

Total Liabilities	=	Total Assets (A: Dec. 2024 )	-	Total Equity (A: Dec. 2024 )
	=	20403.862	-	11914.771
	=	8,489

Zimmer Biomet Holdings's Total Liabilities for the quarter that ended in Mar. 2025 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	2122.782	+	(6083.077	+	840.733
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	9,047

Total Liabilities	=	Total Assets (Q: Mar. 2025 )	-	Total Equity (Q: Mar. 2025 )
	=	20520.107	-	11473.515
	=	9,047

Zimmer Biomet Holdings Total Liabilities Related Terms

Thank you for viewing the detailed overview of Zimmer Biomet Holdings's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Zimmer Biomet Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Zimmer Biomet Holdings Inc (STU:ZIM) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

ZBH:USA ZIM:Germany Z1BH34:Brazil ZBH:Austria

Address

345 East Main Street, Warsaw, IN, USA, 46580

Website

https://www.zimmerbiomet.com

Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.